Stock Events

Stock Events

Benitec Biopharma 

$9.82
22
-$0.20-2% 18:19 Today

Statistics

Day High
10.17
Day Low
9.65
52W High
16.76
52W Low
9.26
Volume
2,018,731
Avg. Volume
-
Mkt Cap
342.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.78
-0.59
-0.41
-0.22
Expected EPS
-0.266667
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-45.55MNet Income

Analyst Ratings

$21.00Average Price Target
The highest estimate is 25.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BNTC. It's not an investment recommendation.
Apple
5
AAPL
Microsoft
5
MSFT
Amazon
5
AMZN
Realty Income
4
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap34.25B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Benitec's gene-silencing technologies.
Ionis Pharmaceuticals
IONS
Mkt Cap7.4B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, making it a direct competitor in the RNA-based therapeutic space.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap9.31B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, competing in the same gene-silencing niche.
Sarepta Therapeutics
SRPT
Mkt Cap1.97B
Sarepta Therapeutics is involved in genetic modulation, including RNA-targeted therapies, positioning it as a competitor in genetic disease treatment.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.66B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other genetic disease treatments, overlapping with Benitec's target market.
CRISPR Therapeutics
CRSP
Mkt Cap5.24B
CRISPR Therapeutics is engaged in gene editing, a different but competing approach to treating genetic diseases compared to Benitec's gene-silencing.
Editas Medicine
EDIT
Mkt Cap396.24M
Editas Medicine operates in the gene editing space, specifically CRISPR, offering alternative genetic disease treatments.
Intellia Therapeutics
NTLA
Mkt Cap1.65B
Intellia Therapeutics is another key player in CRISPR-based gene editing, providing competitive technologies for genetic disease treatment.

About

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
Show more...
CEO
Jerel A. Banks
Employees
24
Country
United States
ISIN
US08205P2092
WKN
000A2P06Q

Listings

MU
DE
BJ93.MU
STU
DE
BJ93.STU
XNAS
US
BNTC
BOATS
BOATS
BNTC.BOATS

0 Comments

Share your thoughts

FAQ

What is Benitec Biopharma stock price today?▼
The current price of BNTC is $9.82 USD — it has decreased by -2% in the past 24 hours. Watch Benitec Biopharma stock price performance more closely on the chart.
What is Benitec Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Benitec Biopharma stocks are traded under the ticker BNTC.
Is Benitec Biopharma stock price growing?▼
BNTC stock has fallen by -10.59% compared to the previous week, the month change is a -21.49% fall, over the last year Benitec Biopharma has showed a -30.02% decrease.
What is Benitec Biopharma market cap?▼
Today Benitec Biopharma has the market capitalization of 342.55M
When is the next Benitec Biopharma earnings date?▼
Benitec Biopharma is going to release the next earnings report on November 16, 2026.
What were Benitec Biopharma earnings last quarter?▼
BNTC earnings for the last quarter are -0.24 USD per share, whereas the estimation was -0.27 USD resulting in a +10.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Benitec Biopharma revenue for the last year?▼
Benitec Biopharma revenue for the last year amounts to 0 USD.
What is Benitec Biopharma net income for the last year?▼
BNTC net income for the last year is -45.55M USD.
How many employees does Benitec Biopharma have?▼
As of September 29, 2026, the company has 24 employees.
In which sector is Benitec Biopharma located?▼
Benitec Biopharma operates in the Health & Wellness sector.
When did Benitec Biopharma complete a stock split?▼
The last stock split for Benitec Biopharma was on July 26, 2023 with a ratio of 1:17.
Where is Benitec Biopharma headquartered?▼
Benitec Biopharma is headquartered in HAYWARD, United States.